DoD awards $1.37B for Monoclonal Antibody LY-COV555, a sole-source pharmaceutical preparation contract

Contract Overview

Contract Amount: $1,373,930,000 ($1.4B)

Contractor: ELI Lilly and Company

Awarding Agency: Department of Defense

Start Date: 2020-10-27

End Date: 2021-06-30

Contract Duration: 246 days

Daily Burn Rate: $5.6M/day

Competition Type: NOT COMPETED

Number of Offers Received: 1

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: MONOCLONAL ANTIBODY LY-COV555

Place of Performance

Location: INDIANAPOLIS, MARION County, INDIANA, 46285

State: Indiana Government Spending

Plain-Language Summary

Department of Defense obligated $1.37 billion to ELI LILLY AND COMPANY for work described as: MONOCLONAL ANTIBODY LY-COV555 Key points: 1. Contract awarded for a critical pharmaceutical product, indicating a significant need for the specified antibody. 2. The sole-source nature of this award warrants scrutiny regarding the absence of competitive bidding. 3. The contract duration of 246 days suggests a focused, short-term requirement for the product. 4. The firm-fixed-price structure aims to provide cost certainty for the government. 5. Awarded by the Department of the Army, this contract supports national health initiatives. 6. The contractor, Eli Lilly and Company, is a major player in the pharmaceutical industry.

Value Assessment

Rating: fair

The contract value of $1.37 billion is substantial, reflecting the scale of pharmaceutical production required. Without comparable sole-source awards for this specific antibody or similar advanced biologics, a direct value-for-money assessment is challenging. However, the firm-fixed-price nature provides some cost control. The absence of competition means there's no direct market benchmark to assess pricing efficiency, making it difficult to determine if taxpayers received the best possible price.

Cost Per Unit: N/A

Competition Analysis

Competition Level: sole-source

This contract was awarded on a sole-source basis, meaning it was not competed. This approach is typically used when only one responsible source can provide the required supplies or services. The lack of competition limits the government's ability to explore alternative suppliers or negotiate potentially lower prices through a bidding process. This raises questions about whether a more competitive approach could have been feasible.

Taxpayer Impact: Sole-source awards can lead to higher costs for taxpayers as the government does not benefit from the price reductions typically achieved through competitive bidding. It also limits opportunities for other qualified businesses to secure government contracts.

Public Impact

The primary beneficiaries are likely healthcare providers and patients who will receive treatments utilizing the Monoclonal Antibody LY-COV555. The contract facilitates the production and supply of a critical pharmaceutical agent, potentially for public health emergencies or specific medical treatments. The geographic impact is primarily centered around the contractor's facilities in Indiana, where the pharmaceutical preparation manufacturing will occur. The contract supports the pharmaceutical manufacturing workforce, potentially creating or sustaining jobs within Eli Lilly and Company's operations.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Sole-source award limits price discovery and potentially increases cost to taxpayers.
Lack of competition raises concerns about whether alternative, potentially more cost-effective, solutions were overlooked.
The significant dollar amount warrants close monitoring of contract performance and delivery.

Positive Signals

Firm-fixed-price contract provides cost certainty for the government.
Award to a known, established pharmaceutical manufacturer suggests a focus on reliability and quality.
Contract supports the production of a potentially vital medical treatment.

Sector Analysis

The pharmaceutical preparation manufacturing sector is characterized by high research and development costs, stringent regulatory requirements, and significant market concentration among a few large companies. This contract falls within the biotechnology and pharmaceutical industry, a critical component of the healthcare sector. Spending in this area is often driven by public health needs, defense medical readiness, and the development of novel therapies. Comparable spending benchmarks would typically involve other large-scale pharmaceutical production contracts for vaccines or therapeutic agents.

Small Business Impact

This contract does not appear to have a small business set-aside component, as indicated by 'sb': false. Furthermore, the contractor, Eli Lilly and Company, is a large business. There is no explicit information provided regarding subcontracting plans with small businesses. Therefore, the direct impact on the small business ecosystem from this specific award is likely minimal, unless the prime contractor actively engages small businesses in its supply chain.

Oversight & Accountability

Oversight for this contract would primarily fall under the Department of the Army's contracting and program management offices. As a definitive contract, it is subject to standard federal procurement regulations and oversight. Transparency is facilitated through contract databases like FPDS. Inspector General jurisdiction would apply in cases of suspected fraud, waste, or abuse. The firm-fixed-price nature simplifies some aspects of financial oversight compared to cost-reimbursement contracts.

Related Government Programs

Monoclonal Antibody Therapies
COVID-19 Therapeutics
Pharmaceutical Manufacturing
Biotechnology Contracts
Department of Defense Medical Supplies

Risk Flags

Sole-source award
High contract value
Potential for price inflation due to lack of competition

Frequently Asked Questions

What is this federal contract paying for?

Department of Defense awarded $1.37 billion to ELI LILLY AND COMPANY. MONOCLONAL ANTIBODY LY-COV555

Who is the contractor on this award?

The obligated recipient is ELI LILLY AND COMPANY.

Which agency awarded this contract?

Awarding agency: Department of Defense (Department of the Army).

What is the total obligated amount?

The obligated amount is $1.37 billion.

What is the period of performance?

Start: 2020-10-27. End: 2021-06-30.

What is the specific medical indication or purpose for Monoclonal Antibody LY-COV555 under this contract?

The provided data does not specify the exact medical indication for Monoclonal Antibody LY-COV555. However, given the timing of the award (October 2020 - June 2021) and the nature of monoclonal antibodies, it is highly probable that this contract was related to the development or supply of treatments for COVID-19. Monoclonal antibodies were a significant focus for therapeutic interventions during the pandemic, aimed at neutralizing the virus or mitigating disease severity. Further investigation into the specific product name and award date would likely reveal its role in the public health response.

Why was this contract awarded on a sole-source basis instead of being competed?

Sole-source awards are typically justified when only one responsible source is capable of providing the required product or service. For specialized pharmaceuticals like monoclonal antibodies, this could be due to unique intellectual property, proprietary manufacturing processes, existing clinical trial data, or urgent national security/public health needs where the time required for a competitive procurement would be prohibitive. In the context of a rapidly evolving health crisis like COVID-19, the government might have prioritized speed and relied on established manufacturers with proven capabilities and existing supply chains to meet immediate demands. A detailed justification for the sole-source determination would be documented by the contracting agency.

What is the track record of Eli Lilly and Company with large federal pharmaceutical contracts?

Eli Lilly and Company is a major global pharmaceutical corporation with a long history of supplying medications and therapies to government agencies, including the Department of Defense and the Department of Veterans Affairs. They have experience with large-scale manufacturing and distribution of various pharmaceutical products. Their track record includes numerous contracts for a wide range of drugs, vaccines, and biologics. While specific details of past performance on large federal contracts would require a deeper dive into contract databases, Eli Lilly is generally recognized as a reliable and capable supplier within the federal healthcare landscape.

How does the $1.37 billion contract value compare to typical spending on similar pharmaceutical preparations?

The $1.37 billion contract value is substantial and reflects a significant investment in pharmaceutical production. When comparing to similar contracts, it's important to consider the specific type of product (e.g., monoclonal antibody vs. a standard vaccine or drug), the scale of production required, and the urgency of the need. Large-scale production of advanced biologics, especially during a public health emergency, can command such high values due to complex manufacturing processes, quality control, and R&D investments. Without specific benchmarks for LY-COV555 or comparable novel therapeutics procured by the government, it's difficult to definitively state if it's high or low, but it indicates a major procurement effort.

What are the potential risks associated with a sole-source award of this magnitude?

The primary risk associated with a sole-source award of this magnitude is the lack of price competition, which could lead to the government paying a premium compared to a fully competed contract. This reduces the potential for cost savings for taxpayers. Additionally, reliance on a single source can create supply chain vulnerabilities; if the contractor faces production issues, delays, or quality control problems, the government's supply could be significantly impacted. There's also a risk that the government might not be leveraging the most innovative or efficient solutions available in the market, as alternative providers were not considered.

What is the expected duration and performance period for this contract?

The contract data indicates a duration of 246 days, with a start date of October 27, 2020, and an end date of June 30, 2021. This suggests a relatively short-term requirement focused on a specific period of production or delivery. The performance period covers approximately 8 months. This timeframe is consistent with fulfilling an immediate need for the specified pharmaceutical product, rather than a long-term supply agreement. The contract type is a definitive contract, implying a firm commitment for the specified period and value.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: NOT COMPETED

Solicitation Procedures: ONLY ONE SOURCE

Solicitation ID: W911QY21R0016

Offers Received: 1

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 1 LILLY CORPORATE CTR, INDIANAPOLIS, IN, 46285

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Manufacturer of Goods, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $1,373,930,000

Exercised Options: $1,373,930,000

Current Obligation: $1,373,930,000

Contract Characteristics

Commercial Item: COMMERCIAL ITEM

Cost or Pricing Data: NO

Timeline